Latest Breaking News On - Melanin containing tissues - Page 4 : comparemela.com

Teva Pharma (TEVA) Reports Results from 3-Year Study Assessing the Safety and Tolerability of AUSTEDO

Teva Announces Results from 3-Year Study Assessing the Safety and Tolerability of AUSTEDO® (deutetrabenazine) Tablets for the Treatment of Chorea Associated with Huntington's Disease

Teva Announces Results from 3-Year Study Assessing the Safety and Tolerability of AUSTEDO® (deutetrabenazine) Tablets for the Treatment of Chorea Associated with Huntington’s Disease - read this article along with other careers information, tips and advice on BioSpace

Teva Announces Largest-Ever Trial to Collect Information from Patients and Physicians About TD, its Impact and Progression Over Time, and Evaluate Treatment-Related Outcomes

3-Year Longitudinal Registry and Study to Assess the Impact of Tardive Dyskinesia and Real-World Use of AUSTEDO® Tablets Initiated . | October 6, 2022

Teva Announces Settlement with Aurobindo Resolving AUSTEDO® (deutetrabenazine) Patent Dispute

TEL AVIV, Israel & PARSIPPANY, N.J. (BUSINESS WIRE) Teva Branded Pharmaceutical Products R&D, Inc. and Auspex Pharmaceuticals, Inc., U.S. affiliates of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), have reached an agreement with Aurobindo to resolve the dispute over Aurobindo’s Abbreviated New Dru.

Teva Announces Settlement with Aurobindo Resolving AUSTEDO® (deutetrabenazine) Patent Dispute